Active Filter(s):
Details:
AxoProtego has licensed the rights for the worldwide development and commercialization of Ethoxyquin and its derivatives (including EQ-6, its lead compound) from The Johns Hopkins University.
Lead Product(s): EQ-6
Therapeutic Area: Neurology Product Name: EQ-6
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020